ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1595

Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration

Manabu Kawata1, Merissa Olmer2, Kristen Johnson3 and Martin K Lotz2, 1Scripps Research Institute, San Diego, CA, 2Scripps Research Institute, La Jolla, CA, 3CALIBR, La Jolla, CA

Meeting: ACR Convergence 2023

Keywords: Animal Model, Chondrogenesis, Genomics and Proteomics, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Osteoarthritis & Joint Biology – Basic Science

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Krüppel-like factors (KLFs) are members of the zinc finger family of transcription factors, which includes 17 members in mammals. We found that expression of KLF4 is dysregulated with progression of osteoarthritis (OA) in human and mouse knee cartilage. Further, we identified KLF4 as a new central transcription factor that regulates protective and regenerative functions in joint tissue cells. We hypothesized that molecules that increase KLF4 expression would be novel therapeutic candidates for OA.

Methods: We performed high throughput drug screening (HTS) using the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library with 11,948 clinical-stage molecules. Hit compounds were tested in joint tissue cells The lead compound was tested in the surgical destabilization of the medial meniscus (DMM) model of OA. As mechanistic studies included transcriptomic and proteomic profiling.

Results: Fifty-one hit compounds were identified in the HTS, and 18 compounds were confirmed in a secondary screen. We validated the 18 hits using SW1353 cells and human chondrocytes, and found that mocetinostat, a class I histone deacetylase (HDAC) inhibitor, had the best profile of biological activities. While mocetinostat upregulated KLF4, KLF2, FOXO1 and cartilage signature genes such as COL2A1, COL11A2, SOX9 and PRG4 in human chondrocytes, meniscal cells and pellet-cultured BMSCs, it down-regulated hypertrophic and catabolic genes, including COL10A1, RUNX2, ADAMTS5 and IL6 (Figure 1 for pellet-cultured BMSCs). Mocetinostat enhanced protective functions in human chondrocytes and synoviocytes through down-regulation of inflammatory and catabolic genes. Intraperitoneal administration of mocetinostat into mice after surgical OA induction significantly improved pain behaviors and reduced the severity of OA histopathological changes in cartilage, meniscus, and synovium (Figure 2 for the summed OARSI scores). We performed RNA-seq and TMT mass spectrometry analysis using mocetinostat-treated TC28a2 cells. While the significantly upregulated genes and proteins showed enrichment of Rap1 signaling pathway and ECM-receptor interaction previously shown to be modulated by KLF4, several unique pathways and terms were also enriched such as PPAR signaling pathway, suggesting novel regulatory mechanisms of HDAC inhibitors.

Conclusion: The class I HDAC inhibitor mocetinostat was identified through the HTS of compounds activating endogenous expression of KLF4. Mocetinostat increased protective and regenerative functions in joint tissue cells and reduced the severity of experimental OA in mice, qualifying it as a novel potential therapeutic candidate for OA.

Supporting image 1

Figure 1. Regulation of chondrogenic and hypertrophic genes by mocetinostat in human BMSC pellets. Human BSMCs were cultured in pellets, and were treated with mocetinostat, or DMSO + TGF-b3. RNA was collected one week after pellet culture. mRA levels are expressed as means +SE, relative to DMSO (n=5 donors). *P<0.05, **P<0.01, Dunnett’s test versus mocetinostat.

Supporting image 2

Figure 2. Therapeutic effects of OA by mocetinostat. Summed OARSI scores for the medial femoral condyle and the tibial plateau are expressed as means +SE (n=15 for each group). *P<0.05 versus DMM + vehicle, Dunn’s test.


Disclosures: M. Kawata: None; M. Olmer: None; K. Johnson: None; M. Lotz: None.

To cite this abstract in AMA style:

Kawata M, Olmer M, Johnson K, Lotz M. Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/pharmacological-modulation-of-kruppel-like-factor-4-reduces-the-severity-of-experimental-osteoarthritis-via-tissue-protection-and-regeneration/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacological-modulation-of-kruppel-like-factor-4-reduces-the-severity-of-experimental-osteoarthritis-via-tissue-protection-and-regeneration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology